Genitourinary Cancers Symposium (ASCO GU)

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

David F. McDermott, MD, associate professor, Department of Medicine, Harvard Medical School/Dana-Farber Cancer Institute, discusses the potential of targeting PD-1 or PD-L1 in patients with kidney cancer

Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.

Sophie D. Fosså, MD, PhD, professor, Department of Oncology, Oslo University Hospital, Norway, discusses a trial analyzing the benefit for radiotherapy/antiandrogen combination in men with locally advanced prostate cancer.

High tumor expression of the protein PD-L1 is independently associated with shorter OS in patients with mRCC receiving treatment with VEGF-targeted therapy.

Two new combinations demonstrated activity in refractory or advanced, previously untreated urothelial carcinoma in phase II evaluations.

Robert Figlin, MD, FACP, discusses updated data on the ADAPT trial, which is an ongoing international phase III randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment in metastatic renal cell carcinoma (mRCC)

Survival, measured as either disease-specific survival or relative conditional survival, has not improved for patients with metastatic urothelial carcinoma despite increasing use of second-line therapies with no formal indication in this setting.

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses validating a whole-blood RNA prognostic signature in mCRPC.

Prednisone, when used in concert with other therapies for the treatment of metastatic castration-resistant prostate cancer, does not raise the risk for severe toxicities, nor does it affect overall survival.

Patients with metastatic castration-resistant prostate cancer (mCRPC) who have detectable serum androgen levels despite treatment with ketoconazole experience prostate-specific antigen (PSA) response to subsequent abiraterone acetate

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.

Extended follow-up of patients with castration-resistant prostate cancer (CRPC) and bone metastases randomized to radium-223 dichloride (Xofigo) in the phase III ALSYMPCA study revealed a continued low incidence of myelosuppression and no association with secondary malignancies.

Leonard Gomella, MD, from the Kimmel Cancer Center Network, Thomas Jefferson University Hospital, provides an update on the dendritic cell cancer vaccine sipuleucel-T in castration-resistant prostate cancer.

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses the androgen receptor inhibitor ODM-201, which is used to treat castration-resistant prostate cancer.

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the results of a study that evaluated the safety of abiraterone acetate combined with docetaxel in patients with metastatic castration-resistant prostate cancer that were presented at the 2014 Genitourinary Cancer Symposium in San Francisco.

An updated analysis, conducted after 11 years of observation, demonstrated continued improved outcomes with the addition of radiotherapy to oral antiandrogen therapy in men with locally advanced prostate cancer.

The androgen-receptor blocker enzalutamide (Xtandi) improves survival by nearly 30% in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of their disease by more than 80%

A vast, pooled retrospective analysis has demonstrated that the use of ASIs may significantly improve survival outcomes in patients with mRCC.

The premature termination of clinical trials in the oncology setting is a problem that continues to vex researchers.

Robert J. Motzer, MD, from Memorial Sloan-Kettering Cancer Center, discusses the COMPARZ trial that compared pazopanib to sunitinib as a first-line therapy for patients with metastatic renal cell carcinoma.

Emmanuel Antonarakis, MBBCh, from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the TAXYNERGY trial that is exploring molecular markers of response in men with mCRPC following an early switch in taxane-based treatment.

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the greater exposure to high-quality healthcare that is provided by the integration of ancillary services into community urology practices.

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.

Robert H. Weiss, MD, from the UC Davis Comprehensive Cancer Center, discusses peroxisome PPAR-alpha as a possible new treatment target for patients with renal cell carcinoma.

William C. Huang, MD, from the New York University Langone Medical Center, discusses findings from a SEER database analysis that compared surveillance to surgical resection in elderly patients with small renal masses.

The 2013 Genitourinary Cancers Symposium was held at the Rosen Shingle Creek, Orlando, Florida, from February 14-16.

Matthew Cooperberg, MD, MPH, from the University of California, San Francisco, discusses the earlier administration of treatment with sipuleucel-T for men with prostate cancer.

Axitinib did not demonstrate superiority over sorafenib as first-line therapy for patients with metastatic renal cell carcinoma, on the endpoint of progression-free survival.